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Abstract
Background: Poxvirus-vectored vaccines against infectious diseases and cancer are currently under
development. We hypothesized that the extensive use of poxvirus-vectored vaccine in future might result
in co-infection and recombination between the vaccine virus and naturally occurring poxviruses, resulting
in hybrid viruses with unpredictable characteristics. Previously, we confirmed that co-infecting in vitro a
Modified vaccinia virus Ankara (MVA) strain engineered to express influenza virus haemagglutinin (HA) and
nucleoprotein (NP) genes with a naturally occurring cowpox virus (CPXV-NOH1) resulted in recombinant
progeny viruses (H Hansen, MI Okeke, Ø Nilssen, T Traavik, Vaccine 23: 499–506, 2004). In this study we
analyzed the biological properties of parental and progeny hybrid viruses.
Results: Five CPXV/MVA progeny viruses were isolated based on plaque phenotype and the expression
of influenza virus HA protein. Progeny hybrid viruses displayed in vitro cell line tropism of CPXV-NOH1,
but not that of MVA. The HA transgene or its expression was lost on serial passage of transgenic viruses
and the speed at which HA expression was lost varied with cell lines. The HA transgene in the progeny
viruses or its expression was stable in African Green Monkey derived Vero cells but became unstable in
rat derived IEC-6 cells. Hybrid viruses lacking the HA transgene have higher levels of virus multiplication
in mammalian cell lines and produced more enveloped virions than the transgene positive progenitor virus
strain. Analysis of the subcellular localization of the transgenic HA protein showed that neither virus strain
nor cell line have effect on the subcellular targets of the HA protein. The influenza virus HA protein was
targeted to enveloped virions, plasma membrane, Golgi apparatus and cytoplasmic vesicles.
Conclusion: Our results suggest that homologous recombination between poxvirus-vectored vaccine
and naturally circulating poxviruses, genetic instability of the transgene, accumulation of non-transgene
expressing vectors or hybrid virus p r o g e n i e s ,  a s  w e l l  a s  c e l l  l i n e / type specific selection against the
transgene are potential complications that may result if poxvirus vectored vaccines are extensively used
in animals and man.
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Background
The family Poxviridae consists of large double stranded
DNA viruses that replicate in the cytoplasm of infected
cells [1,2]. Within this family, vaccinia and cowpox
viruses are members of the genus Orthopoxvirus. Poxvi-
ruses are increasingly being used as vectors for efficient
gene expression in vitro and in vivo [2-4]. The future use
of poxvirus vectors for delivery of prophylactic and thera-
peutic vaccines has raised potential biosafety concerns.
Putative risks associated with the use of genetically modi-
fied poxviruses as vaccines include virulence of the vector,
stability of inserted transgene, potential transmission to
non-target species and recombination between the vac-
cine vector and a naturally circulating poxvirus [5,6]. The
risks of virulence and spread to non-target species have
been addressed in part by the use of attenuated strains like
modified vaccinia virus Ankara (MVA). MVA multiplica-
tion seems to be restricted in most mammalian cells. So
far it has only been shown to carry out full productive
infections in BHK-21 and IEC-6 cells respectively [7,8].
MVA is considered apathogenic even when administered
in high doses to immune deficient animals [9-11]. Several
MVA vectored vaccines against infectious diseases and
cancers are in various phases of field and clinical trials
[12-16].
MVA can be genetically modified by recombination with
a naturally occurring wild type orthopoxvirus (OPV) dur-
ing mixed infection. Alternatively, the transgene in the
MVA vector can be recombined into a replication compe-
tent poxvirus during co-infection. To assess the risk of
recombination, it is essential that the MVA vector and a
naturally circulating poxvirus co-infect the same cell or
host. The potential widespread use of MVA vectored vac-
cines (especially in wild-life and free ranging domestic
animals), and therapeutic vaccination with MVA against
emerging OPV epidemics are likely scenarios for mixed
infection between vaccine strains of OPVs and naturally
circulating relatives. Post exposure application of MVA to
treat pre-existing OPV infection is a likely scenario for co-
infection. Indeed post exposure application of MVA has
been shown to protect against lethal OPV infection [17].
Poxviruses undergo a high frequency of homologous
recombination in the cytoplasm of infected cells [18-22].
Poxvirus recombination, which is inextricably linked with
DNA replication requires 12 bp end sequence homology
between the recombinogenetic templates [23,24]. Thus,
even the highly attenuated MVA can undergo homolo-
gous recombination in non-permissive cells or hosts since
DNA replication is unimpaired. Although homologous
recombination is the method of choice for generating
transgenic MVA vectored vaccines [13], studies on recom-
bination between transgenic MVA vectors and wild type
poxviruses are miniscule. Analysis of co-infection and
recombination between MVA vectored vaccines and wild
type OPVs is a safer model for evaluating the potential
consequences of recombination between poxvirus vec-
tored vaccines and naturally circulating OPVs than using
multiplication competent poxvirus vectors. In addition,
the characterization of hybrid progenies arising from
recombination between transgenic MVA and wild type
OPVs will provide valuable information on poxvirus host
range, morphogenesis, cytopathogenicity (CPE), replica-
tion fitness, transgene stability and transgenic protein
localization.
Previously, we have isolated and genetically mapped
recombinant viruses obtained from co-infection of cells
with a transgenic MVA strain (MVA-HANP) engineered to
express the influenza virus haemagglutinin (HA) and
nucleoprotein (NP) genes and a naturally circulating cow-
pox virus (CPXV-NOH1) [6]. In the present study we ana-
lyzed the biological properties of parental and progeny
hybrid viruses. We show that the transgene or its expres-
sion was lost following serial passage of some of the
hybrid viruses in mammalian cells, and that the resulting
transgene negative virus strains have an enhanced virus
multiplication in several mammalian cell lines. In addi-
tion, the stability of the transgene or the loss of its expres-
sion varies with cell lines used for virus multiplication.
Results
Cell line permissivity, cytopathogenicity and plaque 
phenotypes
To investigate the in vitro host range, cytopathogenicity
and plaque phenotypes of parental and progeny viruses,
thirteen mammalian cell lines from various species and
tissues were infected with viruses under study. The paren-
tal CPXV-NOH1 has a broad host range and multiplied in
all the cell lines (Figure 1A). Caco-2, RK-13, IEC-6 and
Vero cells supported high virus multiplication while virus
production was lower in A549, CHO-K1 and Hutu-80
cells (Figure 1A). MVA-HANP multiplied only in IEC-6
and BHK-21 cells (Figure 1B). Detailed analysis of MVA
multiplication and morphogenesis was described in a pre-
vious report [7]. The in vitro host range of Rec 1 is similar
to CPXV-NOH1 except that higher levels of virus multipli-
cation were obtained in many cell lines (Figure 1C). Rec 2
underwent productive infection in all the cell lines. How-
ever, unlike CPXV-NOH1 and Rec 1, its multiplication
was characterized by high production of extracellular viri-
ons (Figure 1D). In fact, in A549 cells more virions were
released to the medium than intracellular virus particles
(Figure 1D). Compared to CPXV-NOHI, Rec 1 and Rec 2,
Rec 3 had reduced virus multiplication in all the cell lines
(Figure 1E). The transgene negative derivatives of Rec 3
(Rec 3a and Rec 3b) had in vitro host ranges comparable
to Rec 3, except that virus production was more efficient
(Figures 1F, G). Unlike CPXV-NOH1, Rec 1 and Rec 2, no
extracellular virions were detected in FHs74int cellsVirology Journal 2009, 6:55 http://www.virologyj.com/content/6/1/55
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infected with Rec 3 and its transgene negative derivatives
3a and 3b (Figure 1).
CPXV-NOHI produced low, moderate and high CPE in
one, seven and five cell lines respectively (Table 1). MVA-
HANP gave low or no CPE in all the cell lines except BHK-
21 and IEC-6 cells where it produced high and moderate
CPE, respectively. Rec 1 had moderate to very high CPE in
all the cell lines tested except Caco-2. Compared to paren-
tal CPXV-NOH1, Rec 1 showed enhanced CPE in seven
cell lines (Table 1). Similarly, Rec 2 resulted in higher CPE
in most cell lines compared to parental CPXV-NOHI.
Conversely, Rec 3 resulted in lower CPE compared to
CPXV-NOHI in most cell lines except RK-13 and CHO-KI
cells. Interestingly, transgene negative derivatives of Rec 3
(Rec 3a and Rec 3b) produced higher CPE in many cell
lines compared to the transgene positive Rec 3 (Table 1).
In particular, Rec 3b is the most cytopathogenic of virus
strains investigated in this study. The plaque phenotypes
of parental and progeny viruses were examined in thirteen
mammalian cell lines. Previously, we have reported the
plaque phenotypes of these viruses in Vero cells [6]. How-
ever, MVA does not form distinct plaques in Vero cells and
thus comparison of plaque phenotypes of hybrid viruses
was made only with the parental CPXV-NOH1 [6]. There-
fore, we re-examined plaque phenotypes of parental and
hybrid viruses in rat IEC-6, a cell line in which MVA forms
very clear plaques [7]. CPXV-NOH1 produced large lytic
plaques in IEC-6 cells (Figure 2A) and the other twelve cell
lines (data not shown). In permissive IEC-6 cells, MVA-
HANP plaques were small, non-lytic with characteristic
comet (satellite) formation (Figure 2B). The plaque phe-
notype of Rec 1 in IEC-6 cells (Figure 2C) and other cell
lines (data not shown) was similar to CPXV-NOHI except
that plaques were larger in size. Rec 2 produced small
plaques and comets in IEC-6 cells (Figure 2D). Comet for-
mation was enhanced in Rec 2 compared to MVA-HANP
although the size of the primary plaque is larger in the lat-
ter. Rec 3 produced large semi-lytic plaques with some
undetached cells in the center of the plaque (Figure 2E).
Rec 3a plaques were very large and lytic (Figure 2F). Rec
3b produced the largest plaque size in IEC-6 cells (Fig.
2G) and other cell lines and its plaques were characterized
by high level of cell detachment and syncytia formation.
Taken in tandem, the progeny viruses displayed parental
and non-parental characteristics with respect to in vitro
host range, CPE and plaque phenotypes.
Virus multiplication at low and high multiplicity of 
infection (m.o.i)
Multistep multiplication at low m.o.i and single step mul-
tiplication at high m.o.i are standard methods for quanti-
fying infectious virus production [25]. The low m.o.i
analysis was carried out at a m.o.i of 0.01 pfu per cell. The
low m.o.i kinetics of virions produced in the cell and lib-
erated into the medium is summarized in Figures 3A and
Multiplication of parental and progeny viruses in mammalian  cell lines Figure 1
Multiplication of parental and progeny viruses in 
mammalian cell lines. Virus multiplication (fold increase in 
virus titre) was determined by dividing the virus titre at 72 
hpi by virus titre after adsorption. Black bars (virus multipli-
cation in the cell); grey bars (virus in the culture medium). 
The values are mean of two independent experiments 
titrated in duplicate. CPXV-NOH1 (A), MVA-HANP (B), Rec 
1 (C), Rec 2 (D), Rec 3 (E), Rec 3a (F), Rec 3b (G).
Plaque phenotypes of parental virus strains and hybrid virus  progenies in IEC-6 cells Figure 2
Plaque phenotypes of parental virus strains and 
hybrid virus progenies in IEC-6 cells. Confluent IEC-6 
cells were infected with the respective viruses and the HA 
expression was monitored at 36 hpi by immunoperoxidase 
staining of fixed cells. The panels show representative fields 
at approximately × 200 magnification. CPXV-NOHI (A), 
MVA-HANP (B), Rec 1(C), Rec 2 (D), Rec 3 (E), Rec 3a (F), 
Rec 3b (G).Virology Journal 2009, 6:55 http://www.virologyj.com/content/6/1/55
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3B. At low m.o.i, CPXV-NOHI virion production in the
cell increased exponentially after a short lag period, reach-
ing 8.35 logs at 60 hpi (Figure 3A). Release of virions into
the medium was inefficient and was characterized by 24
hours lag period and low virus yield (Figure 3B). MVA-
HANP multiplied poorly in Vero cells (Figures 3A, B).
Intracellular virus production in Rec 1 was very high as
evidenced by very high titre (9.12 logs) and yield (5.4
logs). Although the release of Rec 1 virions from Vero cells
infected at low moi was delayed (36 hpi) compared to
other strains that already released virons (20 hpi or less),
it was a short and spontaneous single burst (Figure 3B).
This suggested that Rec 1 is a very lytic virus. Rec 2 form
small plaques but virion production appears unhindered.
Intracellular virus multiplication was gradually reaching a
titer of 8 logs at late times post infection (Figure 3A).
Expectedly, 35% of Rec 2 total infectivity was liberated
into the medium (Figure 3B). This is not surprising since
Rec 2 is very efficient in producing comets. Multiplication
kinetics of Rec 3 showed that virion production or its
spread was less efficient than other strains infected at
lower m.o.i. Intracellular and extracellular virions pro-
duced by Rec 3 were approximately 1 log or more lower
than that of other strains (Figures 3A, B). Interestingly, the
HA negative viruses (Rec 3a and Rec 3b) derived from Rec
3 by the spontaneous deletion of the HA following serial
passage in Vero cells [6] showed improved levels of virus
multiplication than their ancestor. Indeed at various time
points post infection, Rec 3a and Rec 3b virus titre (in the
cell and medium) were at least one log higher than Rec 3
(Figures 3A, B). At this juncture, we do not know the rea-
son for the increase in virus production in the HA negative
Rec 3a and Rec 3b.
Table 1: Cytopathic effects (CPE) produced by parental and progeny virus strains in mammalian cell lines.
Cytopathic Effects (CPE)a
Cell line Species/tissue CPXV-NOH1 MVA-HANP Rec1 Rec 2 Rec 3 Rec 3a Rec 3b
IEC-6 Rat/small intestine; normal +++ ++ +++ ++++ ++ ++++ ++++
BHK-21 Hamster syrian/kidney; normal ++ +++ ++++ ++++ ++ ++++ ++++
Caco-2 Human/colon; colorectal adenocarcinoma +++ - + ++ +++ +++ ++++
H411E Rat/liver; hepatoma ++ + ++ +++ + +++ +++
FHs74int Human/small intestine; normal +++ - ++ + ++ +++ ++++
Hutu-80 Human/duodenum; adenocarcinoma ++ - ++++ ++++ ++ ++++ ++++
Vero African Green Monkey/kidney; normal +++ + ++++ ++ + ++++ ++++
RK-13 Rabbit/kidney; normal ++ + ++++ +++ ++++ +++ ++++
CHO-K1 Hamster Chinese/ovary ++ - +++ ++++ +++ +++ +++
A549 Human/lung; carcinoma + - ++ ++ + ++ ++
PK15 Pig/kidney; normal ++ + ++ ++ + ++ +++
NMULI Mouse/liver; normal ++ - +++ +++ + ++++ ++++
HEK-293 (CRL-1573) Human/kidney; transformed with adenovirus 5 
DNA
+++ - +++ ++ + ++ ++
a Virus infection was at a m.o.i of 0.05 pfu per cell. CPE was categorized on the following criteria: no difference from uninfected cells (-); low, < 25% 
CPE (+); moderate, 25 to 50%CPE (++); high, > 50 to 75% CPE (+++); very high, > 75 to 100% CPE or high level of cell detachment (++++) [25].
Time course of virus production in Vero cells at low and high  multiplicity of infection Figure 3
Time course of virus production in Vero cells at low 
and high multiplicity of infection. Confluent Vero cells 
were infected with the respective virus strains at low m.o.i 
(0.01 pfu per cell) and high m.o.i (5.0 pfu per cell). Virus pro-
duction in the cell (A) and virus released to the supernatant 
(B) at low m.o.i. Virus production in the cell (C) and virus 
released to the culture medium (D) at high m.o.i. Values are 
means of two independent experiments titrated in duplicates.Virology Journal 2009, 6:55 http://www.virologyj.com/content/6/1/55
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Virus production and spread is influenced by the m.o.i.
Thus low m.o.i multi step conditions may generate differ-
ent multiplication profile from synchronized single step
conditions at high m.o.i [25]. Thus we generated multipli-
cation profiles of test virus strains following synchronized
infection at a m.o.i of 5 pfu per cell. The results are sum-
marized in Figures 3C and 3D. CPXV-NOHI has similar
multiplication kinetics with all progeny viruses from
adsorption to 24 hpi, although Rec 3 has the lowest intra-
cellular and extracellular virus titres (Figures 3C, D). MVA-
HANP performs limited virus multiplication in Vero cells.
Consistent with what was obtained under multi-step con-
ditions, transgene negative progenies of Rec 3 (Rec 3a and
Rec 3b) have higher levels of virus multiplication com-
pared to Rec 3 (Figures 3C, D). Thus, compared to the HA
positive progenitor strain (Rec 3), the HA negative deriva-
tives (Rec 3a and Rec 3b) have enhanced virus multiplica-
tion at both low and high m.o.i.
Stability of the transgene in mammalian cells
Since virus tropism is dependent on the host or cell type,
we hypothesized that the stability of the influenza virus
HA insert in the transgenic viruses may vary in different
cell types or lines. To our knowledge, the stability of the
transgene in MVA vectored vaccines in different cell types
or hosts has not been reported. To address this hypothe-
sis, transgene positive viruses were passaged in Vero and
IEC-6 cells for five times at a m.o.i of 0.01 pfu per cell.
Consistent with our previous report, the HA phenotype of
Rec 3 was unstable in Vero cells [6]. By the 4th passage,
HA + plaques were undetected in Vero cells (Figure 4A).
The HA phenotype of Rec 1 in Vero cells was stable up to
passage 3. However, by passage 5, only 58% of Rec 1
plaques were HA + (Figure 4A). The HA + phenotype of
Rec 2 was very stable in Vero cells across several passages
(Figure 4A). These results suggested varying degrees of sta-
bility of the transgene in the progeny transgenic viruses.
The stability of the HA + phenotype of MVA-HANP in
Vero cells was not included because of low virus titres. The
HA + phenotype of all transgenic viruses including MVA-
HANP was unstable in IEC-6 cells (Figure 4B). The highest
level of instability was observed with MVA-HANP and Rec
3. In both viruses, the HA + plaques were undetectable at
passage 3 (Figure 4B). Beyond passage 3, the HA + pheno-
type of Rec 1 and Rec 2 were unstable to the extent that
approximately 20% of the plaques were HA + at passage 5
(Figure 4B). Also, the reduction in the number of HA
expressing viruses (MVA-HANP, Rec 3) was accompanied
by a dramatic increase in the number of none HA express-
ing viruses (data not shown). There was no significant var-
iation in the titre of each transgenic virus in Vero or IEC-6
cells at each serial passage (data not shown). Thus, these
results suggest that the cell line or cell type used for virus
multiplication might influence the stability of the trans-
gene inserted into poxvirus vectors or determine the speed
at which the expression of the transgene is lost. In addi-
tion, it shows the selection and accumulation of virus
mutants that have lost the transgene or its expression.
Shape and size of virions
The shape and size of negatively stained purified virions
were determined in order to ascertain whether there are
differences in the virion 2D architecture of the virus
strains under study. The results are shown in Figure 5 and
Table 2. The virions of CPXV-NOHI were brick shaped
measuring 293 ± 27 nm × 229 ± 23 nm in size (Figure 5A,
Table 2). Virions of CPXV-NOH1 were slightly smaller
than what has been reported for strains of vaccinia virus
[26-28]. Conversely, half of the virions of MVA-HANP
were brick shaped (314 ± 23 nm × 256 ± 18 nm) while the
other half were round shaped with dimensions measuring
255 ± 28 nm × 243 ± 29 nm (Figure 5B, Table 2). Virions
obtained from Rec 1, Rec 3, Rec 3a and Rec 3b resemble
that of CPXV-NOH1 in being mostly brick shaped. Unlike
CPXV-NOH1, a small percentage of virions obtained from
the aforementioned progeny viruses have round shape
(Figure 5, Table 2). Apparently the virions of Rec 2 appear
to be a mixture of what was obtained from the parental
strains. Two thirds of Rec 2 virions were brick shaped and
the remaining one third were round in shape (Figure 5D,
Table 2). The results indicated that the brick shape is the
major virion shape in all virus strains except MVA-HANP.
Virus morphogenesis
We carried out detailed analysis of the morphogenesis of
the virus strains under study by electron microscopy. Rel-
ative and absolute numbers of various mature and imma-
ture viral forms were determined at different times post
Stability of the HA transgene in mammalian cell lines Figure 4
Stability of the HA transgene in mammalian cell 
lines. The stability of the influenza virus transgene inserted 
into MVA and hybrid progenies was assayed indirectly by 
monitoring the HA phenotype. Serial passage of transgenic 
virus strains in Vero (A) and IEC-6 (B) cells.Virology Journal 2009, 6:55 http://www.virologyj.com/content/6/1/55
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Negatively stained purified virions of parental virus strains and hybrid progenies Figure 5
Negatively stained purified virions of parental virus strains and hybrid progenies. CPXV-NOHI (A), MVA-HANP 
(B), Rec 1 (C), Rec 2 (D), Rec 3 (E), Rec 3a (F), Rec 3b (G). Arrows (round virions). Bars, 200 nm (A-G).Virology Journal 2009, 6:55 http://www.virologyj.com/content/6/1/55
Page 7 of 13
(page number not for citation purposes)
infection. The kinetics of mature virus production in Vero
cells is depicted in Figure 6. MVA-HANP results were not
included because a very low level of mature virus forms
were produced in Vero cells [7]. Assembly of CPXV-NOHI
and hybrid progenies was similar to what have been
reported for strains of vaccinia virus [7,29,30]. Differences
existed in the abundance of mature virus forms produced
by CPXV-NOHI and progeny viruses. The intracellular
mature virus (IMV) is the major mature virus type pro-
duced in CPXV-NOH1 infected cells accounting for 87%
of virion forms (IMV, IEV, CEV) at 24 hpi (Figure 6A).
Intracellular enveloped virus (IEV) and cell associated
enveloped virus (CEV) represented 4% and 9% respec-
tively of virion forms produced in CPXV-NOH1 infected
cells (Figure 6A). Similarly, 95% of virions produced by
Rec 1 at 24 hpi were IMVs (Figure 6B). However in Rec 2,
a higher proportion of IMVs were converted to enveloped
forms such that at 24 hpi, CEV is the predominant form
representing 55% of virion forms produced (Figure 6C).
Rec 3 appeared defective in the production of enveloped
virions. At 18 and 24 hpi, less than 1% of Rec 3 virions
were IEV or CEV (Figure 6D). Transgene negative deriva-
tives of Rec 3 (Rec 3a and Rec 3b) were efficient in the pro-
duction of enveloped virions. The enveloped forms (IEV
and CEV) accounted for approximately 50% of virion
types produced by Rec 3a and Rec 3b respectively at 24 hpi
(Figures 6E, F).
Localization of the transgenic protein
We used immunogold cryo electron microscopy to track
the localization of influenza virus HA protein produced
by transgenic poxviruses in infected cells. The cellular and
viral location of the transgenic protein was the same for all
transgenic viruses (MVA-HANP, Rec 1, Rec 2, Rec 3), and
was also independent of cell line used for virus cultiva-
tion. The transgenic protein was absent in IMVs and
immature viruses (Figures 7A, C). The influenza virus HA
protein was concentrated on the plasma membrane (Fig-
ures 7A–F), Golgi apparatus (Figure 7D), trans-Golgi
membrane (Figure 7C), CEVs (Figures 7B, E), and EEVs
(Figures 7F). Gold particles were also present in cell-asso-
ciated vesicles (Figure 7D), vacuoles, cytoplasmic vesicles
and exocytic vesicles (data not shown). Overall, the influ-
enza virus HA protein was targeted to enveloped virions
and cellular compartments associated with the down
stream exocytic pathway. Also the transgenic HA protein
targets are independent of virus backbone expressing the
Table 2: Shape and size of negatively stained purified virions.
Shape and dimensions of purified virionsa
Virus strain Brick Round
N (%) Length (nm) Width (nm) N (%) Length (nm) Width (nm)
CPXV-NOH1 50 (100) 293 ± 27 229 ± 23 0 (0) - -
MVA-HANP 25 (50) 314 ± 23 256 ± 18 25 (50) 255 ± 28 243 ± 29
Rec 1 43 (86) 303 ± 17 244 ± 15 7 (14) 272 ± 35 264 ± 35
Rec 2 32 (64) 287 ± 15 237 ± 16 18 (36) 253 ± 19 238 ± 18
Rec 3 42 (84) 300 ± 18 235 ± 12 8 (16) 251 ± 15 238 ± 18
Rec 3a 43 (86) 292 ± 15 229 ± 14 7 (14) 257 ± 11 243 ± 8
Rec 3b 47 (94) 302 ± 13 240 ± 13 3 (6) 257 ± 6 243 ± 6
a 50 virions from each virus strain were randomly selected and their shapes and sizes determined.
Relative amount of mature virus forms produced by respec- tive virus strains in Vero cells Figure 6
Relative amount of mature virus forms produced by 
respective virus strains in Vero cells. Virion forms pro-
duced at different times post infection were quantified by 
electron microscopy as described in methods. IMV, IEV and 
CEV were counted in 50 randomly chosen sections of 
infected cells. The values represent percentage of each virus 
form relative to the total number of virus forms counted. 
IMV, intracellular mature virus; CEV, cell associated envel-
oped virus; EEV, extracellular enveloped virus. CPXV-NOHI 
(A), Rec 1 (B), Rec 2 (C), Rec 3 (D), Rec 3a (E), Rec 3b (F).Virology Journal 2009, 6:55 http://www.virologyj.com/content/6/1/55
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transgene as well as the cell line used for virus multiplica-
tion.
Discussion
In this work we have investigated biological properties of
progeny hybrid viruses obtained from recombination in
vitro with a transgenic MVA candidate vaccine and a nat-
urally circulating cowpox virus. The hypothesis of this
work is that the extensive use of poxvirus-vectored vac-
cines in future might result in natural in vivo co-infection
and recombination between poxvirus-vectored vaccines
and naturally circulating orthopoxviruses resulting in
hybrid viruses with non-parental characteristics. MVA and
a naturally circulating cowpox virus were used as parental
strains to test this hypothesis in vitro. MVA is arguably the
vector of choice for antigen delivery [31], and the wide
spread use of MVA vectored vaccines (especially in wild
life and domestic animals) in the future is highly likely.
Cowpox virus is the ancestor of other OPVs, has broad
host range, and contains the most complete repertoire of
immunomodulators [32-34]. Unlike vaccinia virus where
DNAemia or viremia seems to be an extremely rare event
in vaccinees [35], DNAemia in patients with localized
symptoms of cowpox virus infection seem not to be a rare
event [36]. Indeed cowpox virus DNA was detected in
whole blood of two independent patients at 4 weeks post
infection [36]. Persistence of cowpox virus DNA in
infected individuals increases the likelihood of recombi-
nation during co-infection with a poxvirus-vectored vac-
cine. Thus homologous recombination between MVA
vectored vaccine and a naturally circulating cowpox virus
(or other orthopoxviruses) can occur and such a recombi-
nation has the potential of generating novel hybrid
viruses that will elucidate our understanding of the biol-
ogy of recombinant poxviruses, as well as the putative sce-
narios that might arise following the release of genetically
modified poxviruses in the wild.
CPXV-NOH1 underwent productive infection in all the
thirteen mammalian cell lines used in this study. This is
consistent with the broad host range of other cowpox
virus strains [37,38]. The progeny viruses have cell line
tropism similar to CPXV-NOHI, but not to MVA-HANP.
Although few host range genes have been identified in
cowpox virus [39], sequence analysis of OPV genomes
indicated that host range genes cluster at the genome ter-
mini [32,40]. Our previous work suggested that all the
progeny viruses derived their genome termini from CPXV-
NOH1 [6]. Thus the hybrid viruses might have derived
their host range genes from CPXV-NOH1. With the excep-
tion of Rec 3, progeny viruses have higher levels of CPE in
most mammalian cell lines than the parental strains. A
possible explanation is that progeny viruses have a more
effective mechanism for the shutdown of host protein
synthesis.
Progeny viruses displayed plaque phenotypes different
from parental strains. The plaque phenotypes of the prog-
enies were reproducible in all the cell lines (data not
shown). Large lytic plaques are often associated with effi-
cient cell to cell spread in cell cultures while small plaques
may indicate inefficient cell to cell spread [41,42]. The
genetic basis of the plaque phenotypes in the parental and
progeny viruses is unknown. However, in vaccinia virus
Western Reserve (VACV-WR), it has been demonstrated
that five EEV proteins (gene products of A33R,  A34R,
A56R, B5R, F13L) and two IEV proteins (A36R, F12L) may
be involved in determining plaque phenotypes [43-49].
Although functionally intact EEV and IEV membrane pro-
Cellular and viral localization of the influenza virus haemag- glutinin protein Figure 7
Cellular and viral localization of the influenza virus 
haemagglutinin protein. Vero cells were infected with 
MVA-HANP and HA + hybrid progenies and processed for 
immunoelectron microscopy as detailed in methods. Rec 1 
infected Vero cells (A, B) and Rec 2 infected Vero cells (C-F). 
(A): arrow (plasma membrane), arrow heads (IMVs); (B): 
arrow (plasma membrane), arrow heads (CEVs); (C): arrow 
(plasma membrane), large arrow head (trans-Golgi mem-
brane), small arrow heads (immature viruses); (D): arrow 
(plasma membrane), large arrow heads (Golgi apparatus), 
small arrow (cell associated vesicle); (E): arrow (plasma 
membrane), arrow heads (CEVs); (F): arrow (plasma mem-
brane), large arrow heads (EEVs), small arrow head (plasma 
membrane projection). The same results were obtained with 
MVA-HANP and Rec 3 (data not shown). IMV, intracellular 
mature virus; CEV, cell associated enveloped virus; EEV, 
extracellular enveloped virus. Bars, 100 nm (A-F).Virology Journal 2009, 6:55 http://www.virologyj.com/content/6/1/55
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teins are associated with large plaque phenotype, they are
insufficient in determining plaque size per se [50]. It has
also been reported that the production of actin tails is the
major factor correlating with plaque size [51]. Rec 2
plaques were characterized by the formation of comets.
Comet formation was present, albeit to a lower degree in
the parental MVA-HANP. Thus it is plausible that the
genes for comet formation in Rec 2 were derived from
MVA-HANP. In vaccinia virus IHD, comets are due to
point mutation in the A34R open reading frame (ORF) or
a second site mutation in the A33R and B5R ORFs [52,53].
Rec 3b plaques displayed high degree of syncytium forma-
tion, a trait not observed in the parental strains and other
progeny viruses. Mutation in the A56R is known to cause
syncytia in vaccinia virus [54].
Three experimental observations made in this study have
potential relevance for the release of genetically modified
poxviruses into the ecosystem as well as recombination
between transgenic poxviruses and naturally occurring rel-
atives. Firstly, the transgene is deleted at high frequency in
Rec 3 and MVA-HANP probably as a result of adaptation
to the cell lines. Secondly, the viruses that have lost the
transgene have higher virus multiplication compared to
the transgene positive progenitor strain. Thirdly, there is
variation in the stability of the transgene or its phenotype
in different cell lines. The HA phenotype of Rec 2 was very
stable in African Green Monkey derived Vero cells but
became unstable in rat derived intestinal IEC-6 cells. The
loss of the transgene/transgene phenotype as part of adap-
tation to new cells or hosts, the subsequent positive selec-
tion and accumulation of none transgene expressing virus
mutants might compromise the efficacy of poxvirus vec-
tored vaccines. The loss of the transgene will likely result
in less effective vaccine since there will be less antigen to
elicit robust immune responses. However since MVA
undergoes abortive infection in most mammalian cell
types, the accumulation of none transgene expressing
viruses in the vaccinated hosts seem unlikely. The loss of
the transgene or its phenotype and subsequent accumula-
tion of none transgene expressing vector will be a likely
problem for poxvirus vaccines based on replication com-
petent vaccinia virus. The apparent variation in the stabil-
ity of the HA  transgene or the HA phenotype across
different cell lines raises the possibility that the transgene
inserted into poxviruses may have varying stability in dif-
ferent hosts. Although, spontaneous deletion [6] and
truncation [55] of transgenes have been observed in some
candidate MVA vectored vaccines, this is the first report
showing that the same MVA or CPXV/MVA vectored vac-
cines was stable in one cell line and unstable in the other.
Thus, our findings suggest that there is a host cell selection
against the transgene. We have no explanation for the dif-
ferential loss of the HA expression in different cell lines
and among different viruses following serial passage.
However, we speculate that the structure of the inserted
HA transgene, the promoters driving the HA expression,
the direction of the inserted HA transgene relative to the
surrounding genes, the inherent stability/instability of the
genetic locus at which the HA was inserted and the host
cell responses to the HA protein are some of the factors
that might affect the stability of the HA transgene or the
loss of the HA expression following serial passage of the
transgenic viruses. Genome wide mapping of these
recombinant viruses will shed light on the genetic basis
for the biological observations made in this study.
The purified virions of CPXV-NOH1 are brick shaped with
highly corrugated surface similar to the structure of VACV-
WR [28]. The virions of MVA-HANP are pleomorphic with
half of the virions being brick shaped and the other half
round. The observation is in concert with a previous
report [27]. A 3D reconstruction of VACV-WR virions
claimed that all IMVs are brick shaped and the observa-
tion of varied shapes in earlier studies is due to the limita-
tion of 2D imaging [26]. The round form observed in this
study for MVA-HANP and the hybrid viruses (Figures 5B,
D, E) is very close to a circle such that the difference
between the length and width is 15 nm or less (Table 2).
However, 2D measurements as done in this study can be
affected by the angle of tilt as well as the plane at which
the virions lie on the grids. Thus, our finding of spherical
or round forms of virions especially in MVA need to be
confirmed by 3D reconstruction of MVA and other OPV
strains.
IMV is the major viral form produced in Vero cells
infected with CPXV-NOH1. The dominance of IMVs over
the enveloped forms may not be unconnected with the
fact that CPXV-NOH1 produces V+ A-type inclusion (ATI)
in infected cells (data not shown). It has been suggested
that IMVs marked for sequestration into ATI may not dif-
ferentiate into IEVs, CEVs or EEVs [56]. Like CPXV-NOH1,
IMVs constitute over 90% of virions produced in Vero
cells infected with Rec 1 at various times post infection.
However in Rec 2, the percentage of enveloped forms (IEV
and CEV) is higher than that of IMV. Probably, the trans-
Golgi network (TGN) wrapping and transport of IEV on
microtubules is very efficient in Rec 2. Rec 3 on the other
hand produces very low number of IEV or CEV and may
be defective in the wrapping of IMV by the TGN. In Rec 3a
and Rec 3b, the proportions of IMV and enveloped virions
at 24 hpi were almost equal. Kinetics of virion formation
in Rec 3a indicated high percentage of CEVs even though
that of IEVs is low. It seems that some of the CEVs
observed in Rec 3a infected cells were produced by plasma
membrane budding of IMV rather than fusion of IEV
outer envelope with the plasma membrane. Budding of
IMVs through the plasma membrane has been shown toVirology Journal 2009, 6:55 http://www.virologyj.com/content/6/1/55
Page 10 of 13
(page number not for citation purposes)
be an alternative mechanism for the production of CEVs
[57].
The incorporation of influenza virus HA protein into the
CEV and EEV of transgenic viruses has potential biosafety
and immunological implications. Although foreign pro-
tein on the surface of CEVs and EEVs may enhance the
humoral immune response of the host [58], they may also
alter the host range or cell tropism of the transgenic MVA.
Although MVA is host restricted and may not form suffi-
cient CEVs/EEVs in human cells, the transgene on the
MVA vector can be inserted by homologous recombina-
tion into another OPV with broad host range during
mixed infection. Indeed we have shown in this work that
the CEV and EEV of hybrid viruses incorporated the trans-
genic protein on their surface. We assume that the locali-
zation of the transgenic protein on CEV/EEV but not IMV
or immature viruses is because the former derived its
envelope from TGN or the plasma membrane [57,59].
Both the TGN and plasma membrane were heavily
labeled with gold particles. The cellular localization of the
influenza virus transgenic protein is in agreement with
other reports [60,61]. The lack of gold particles on IMVs
and immature viruses suggests that the IMV membrane is
not derived from cellular membranes associated with the
exocytic pathway.
Conclusion
We have shown that recombinant viruses obtained from
co-infection of cells with MVA vectored influenza vaccine
and a naturally circulating cowpox virus displayed paren-
tal, but also potentially important non-parental character-
istics, which were not predictable from the outset. A major
observation is that the transgene negative viruses have
enhanced multiplication compared to the transgene posi-
tive progenitor virus strain, and that the host cell type may
affect the stability of the transgene or its phenotype
Methods
Cells, viruses, and antibodies
All cell lines were purchased from the American Type Cul-
ture Collection (ATCC). Cells (Table 1) except A549 were
cultured under conditions suggested by ATCC. A549 cells
were propagated in Hams F12 medium supplemented
with 20% foetal bovine serum (FBS) (Invitrogen AS, Karl-
ruhe, Germany). The CPXV-NOH1 was originally isolated
from a woman with necrotic ulcer [62]. MVA-HANP was
provided by Dr. Bernard Moss, National Institute of
Health, USA. The genome of MVA-HANP contains influ-
enza virus (A/PR/8/34) HA and NP inserts [63]. CPXV-
NOHI and MVA-HANP were parental viruses used for co-
infection of BHK-21 cells. The isolation and restriction
enzyme mapping of parental and progeny hybrid viruses
was reported elsewhere [6]. The progeny hybrid viruses
are CPXV/MVA-Rec1 (Rec 1), CPXV/MVA-Rec2 (Rec 2),
CPXV/MVA-Rec3 (Rec 3), CPXV/MVA-Rec3a (Rec 3a) and
CPXV/MVA-Rec3b (Rec 3b). Rec 3a and Rec 3b are trans-
gene negative derivatives of Rec 3 [6]. The stock of paren-
tal and progeny viruses except MVA-HANP were prepared
from infected Vero cells. MVA-HANP stock was prepared
from infected BHK-21 cells. Anti influenza virus HA mon-
oclonal antibody, H28E23 was a gift from Dr. Bernard
Moss.
Immunostaining
Plaques of viruses carrying the influenza virus HANP
transgenes were visualized by immunostaining as
described previously [6]. Briefly, virus infected cells were
fixed in 1:1 solution of methanol: acetone for 2 minutes.
Anti influenza virus monoclonal antibody H28E23 was
used as primary antibody in 1: 500 dilution. The second-
ary antibody, rabbit anti mouse IgG conjugated with per-
oxidase (Dako, Glostrop, Denmark) was used in 1:200
dilution. Both antibodies were diluted in phosphate buff-
ered saline (PBS) supplemented with 3% FBS. DAB Perox-
idase (Sigma Fast™ 3, 31diaminobenzidine tablet sets) was
used as substrate (Sigma Aldrich Chemie Gmbh, Stein-
hein Germany). This staining method was used to deter-
mine the titre of the transgene positive virus strains under
low and high m.o.i.
Plaque Assay
The titres of transgene negative viruses under low and
high m.o.i were determined by plaque assay as described
previously [53]. Virus was adsorbed to cell monolayer for
one hour at 37°C. The inoculum was removed and
infected cells were incubated in fresh medium supple-
mented with 2.5% FBS at 37°C in a 5% CO2 atmosphere.
After 36 hours, the medium was removed, and the
infected cells were stained with crystal violet (0.1% in
20% ethanol) for 30 minutes. The cells were washed and
air-dried.
Cell Line Permissivity Assay
Thirteen mammalian cell lines (Table 1) in 25 cm2 tissue
culture flasks were infected with parental and progeny
viruses at a m.o.i of 0.05 pfu or IU per cell. Following
adsorption for one hour, the inocula were removed and
cells were washed twice in PBS. Fresh medium supple-
mented with 2.5% FBS were added and incubation was
carried out for 72 hpi. Cells and medium (supernatant)
were harvested. Viruses in the cells were released by three
cycles of freeze-thawing and brief sonication. Virus multi-
plication and CPE were quantified as reported previously
[25].
Kinetics of virus multiplication
Vero and IEC-cell monolayers in 25 cm2 TC flasks were
infected with respective virus strains at low (0.01 pfu/cell)
and high (5.0 pfu/cell) m.o.i respectively. After adsorp-Virology Journal 2009, 6:55 http://www.virologyj.com/content/6/1/55
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tion for one hour at 37°C, the inocula were removed.
Infected cells were washed twice in PBS and incubated in
appropriate medium supplemented with 2.5% FBS at
37°C in a 5% CO2 atmosphere. At multiple times post
infection, cells and supernatant were harvested. Virus titre
in the cell lysate and supernatant were determined by
plaque assay and immunostaining.
Transgene Stability Assay
The stability of the influenza virus HA insert present in the
genome of the transgene positive viruses was monitored
indirectly by immunostaining. Plaque purified transgene
positive virus strains were passaged many times in Vero
and IEC-6 cells at a m.o.i of 0.01 pfu per cell. After each
passage, the infectious titre and the number of HA posi-
tive and HA negative plaques were quantified by immu-
nostaining. Back titration of MVA-HANP was done in IEC-
6 monolayers while that of other transgene positive virus
strains were carried out in Vero cells.
Transmission Electron Microscopy
Cell monolayers in six well tissue culture plates (NUNC
Sweden) were infected with parental and progeny viruses
at a m.o.i of 5 pfu per cell. Adsorption was for one hour at
4°C. The cells were washed thrice in PBS and incubated in
fresh medium containing 2.5% FBS at 37°C in 5% CO2
atmosphere. At 6, 12, 18, and 24 hpi, the medium was
removed. Infected cells were rinsed with fresh medium,
and fixed in MacDowells solution, pH 7.4 containing 1%
glutaraldehyde and 4% formaldehyde in PBS. Fixed cells
were processed for electron microscopy as reported else-
where [64]. Mature and immature forms of parental and
progeny viruses were counted in 50 cell sections that were
infected. Absolute and relative amount of viral forms were
calculated. Collection of images from thin sections was
done using JEOL 1010 electron microscope operating at
an accelerating voltage of 100 KV.
Negative Staining
Parental and progeny virions were semi-purified from
infected cells by pelleting through a sucrose cushion [65].
Purified virions were negatively stained with 1% phos-
photungstic acid, pH 6.2. Stained virions were adsorbed
to formvar coated grids. Virions were visualized in a JEOL
JEM – 1010 electron microscope. The shape and dimen-
sions of 50 virions were determined for each of the virus
strains under study.
Cryo-immunogold Electron Microscopy
Monolayers of Vero, IEC-6, and A549 cells were infected
with parental and progeny virus strains at a m.o.i of 5 pfu
or IU per cell. Virus adsorption was for one hour at 4°C.
Cells were washed in PBS and incubated in a fresh
medium supplemented with 2.5% FBS under standard
conditions. At 12 and 24 hpi, the culture medium was
removed and infected cells were rinsed with PBS, fixed
overnight in 4% formaldehyde – 0.1% glutaraldehyde in
Hepes buffer, pH 7.4. Fixed cells were pelleted, resus-
pended in 10% gelatin and infiltrated in 2.3 M sucrose.
Infiltrated cells were processed for pre-embedding immu-
nogold labeling [66]. Anti-influenza virus HA mono-
clonal antibody H28E23 diluted 1: 400 in 1% cold water
fish gelatin, CWFSG (Sigma G-7765) was used as the pri-
mary antibody. The influenza virus HA monoclonal anti-
body was detected with rabbit anti mouse IgG (diluted 1:
400 in CWFSG) conjugated to 10 nm gold particles. The
localization of the transgenic protein in the cellular and
viral structures was documented with JEOL 1010 electron
microscope.
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